

TABLE 177: NAIVE SVR GENOTYPE 4 NON-CIRRHOTIC WITH SOF12 PR12 ADDED: ODDS RATIOS, RELATIVE RISKS, AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR 48	1.12 (0.17 to 1.52)	8.00 (–54.10 to 33.38)
SOF24 + RBV24		1.27 (0.90 to 1.47)	17.41 (–6.87 to 30.08)
SOF12 PR12		1.48 (1.27 to 1.55)	31.41 (17.51 to 35.32)
SOF24 + RBV24	SOF12 + RBV12	1.12 (0.77 to 7.01)	8.58 (–20.31 to 67.59)
SOF12 PR12		1.31 (0.94 to 8.84)	22.55 (–6.16 to 85.03)
SOF12 PR12	SOF24 + RBV24	1.16 (0.96 to 1.64)	13.27 (–4.10 to 37.77)
Random effect model	Residual deviance	5.703 vs. 6 data points	
	Deviance information criteria	35.428	
Fixed effect model	Residual deviance	5.68 vs. 6 data points	
	Deviance information criteria	35.411	

Cri = credible interval; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.